Literature DB >> 1532331

Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.

E Eigenbrodt1, M Reinacher, U Scheefers-Borchel, H Scheefers, R Friis.   

Abstract

As a common characteristic of tumor cells, as well as of normal proliferating cells in the G1-phase of cell cycle, one finds constitutive high levels of all the glycolytic metabolites arising between glucose 6-phosphate and phosphoenolpyruvate. Thus, it is that the phosphometabolites fructose 1,6-bisphosphate, ribose 5-P, P-ribose-PP, NAD, GTP, CTO, UTP, UDP-glucose, glycerol 3-P, glycerol phosphocholine and glycerol phosphoethanolamine are useful in the 31P-nuclear magnetic resonance (NMR) detection of solid tumors in animals and man. This expansion of phosphometabolites is achieved during tumor formation as a result of reductions in levels of enzymes degrading phosphometabolites, owing to the decline in the glycerol 3-P hydrogen shuttle, and as a consequence of alterations in the glycolytic isoenzyme equipment. Tumor cells typically express a particular isoenzyme of pyruvate kinase called type M2 (K) at high levels. This isoenzyme is subject to a complex regulation by amino acids, by fructose 1,6-bisphosphate, and by hormonal- and oncogene-dependent phosphorylation. Pyruvate kinase type M2 is a substrate for the oncogene encoded PP60v-src-tyrosine kinase. A drastic decrease in the affinity for its substrate phosphoenolpyruvate found after transformation by the src-oncogene can be explained as a consequence of the phosphorylation of pyruvate kinase in serine and tyrosine. These phosphorylations induce the breakdown of tetrameric pyruvate kinase to the trimeric and dimeric forms. Unlike the tetrameric form, the dimeric form as a low affinity for phosphoenolpyruvate. Partial inactivation of pyruvate kinase and enolase on the one hand, and a hyperactivation of hexokinase and phosphofructokinase on the other hand, lead to an expansion of all metabolites. Only when these metabolites attain high levels, thereby assuring a sufficient supply of metabolites for RNA, DNA, lipid, and complex carbohydrate synthesis, can cell proliferation proceed. This accumulation of metabolites in the G1-phase cells has been termed a "metabolic budget system" because it senses not only the actual nutrient levels, but also the supply over a period of time. Monoclonal antibodies specific for the dimeric form of pyruvate kinase type M2 can be used for the immunohistological detection of tumor cells. The amount of the dimeric form in tumor cells closely correlates with the degree of malignancy and can be used for a nonspecific detection of tumors based on assays performed with patient's plasma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532331

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  67 in total

Review 1.  Human pyruvate kinase M2: a multifunctional protein.

Authors:  Vibhor Gupta; Rameshwar N K Bamezai
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

Review 2.  Intersections of post-transcriptional gene regulatory mechanisms with intermediary metabolism.

Authors:  Waqar Arif; Gandhar Datar; Auinash Kalsotra
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-11       Impact factor: 4.490

Review 3.  Pyruvate kinase: Function, regulation and role in cancer.

Authors:  William J Israelsen; Matthew G Vander Heiden
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

4.  Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase.

Authors:  Stefan Siwko; Daria Mochly-Rosen
Journal:  Int J Biochem Cell Biol       Date:  2007-01-24       Impact factor: 5.085

5.  Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation.

Authors:  Katherine Tech; Andrey P Tikunov; Hamza Farooq; A Sorana Morrissy; Jessica Meidinger; Taylor Fish; Sarah C Green; Hedi Liu; Yisu Li; Andrew J Mungall; Richard A Moore; Yussanne Ma; Steven J M Jones; Marco A Marra; Matthew G Vander Heiden; Michael D Taylor; Jeffrey M Macdonald; Timothy R Gershon
Journal:  Cancer Res       Date:  2017-05-17       Impact factor: 12.701

6.  Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein.

Authors:  W Zwerschke; S Mazurek; P Massimi; L Banks; E Eigenbrodt; P Jansen-Dürr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.

Authors:  Le Zhang; Justine Bailleul; Taha Yazal; Kevin Dong; David Sung; Amy Dao; Laura Gosa; David Nathanson; Kruttika Bhat; Sara Duhachek-Muggy; Claudia Alli; Milana Bochkur Dratver; Frank Pajonk; Erina Vlashi
Journal:  Breast Cancer Res Treat       Date:  2019-08-01       Impact factor: 4.872

8.  L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases.

Authors:  U Brinck; E Eigenbrodt; M Oehmke; S Mazurek; G Fischer
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.

Authors:  Maurizio Ventrucci; Antonio Cipolla; Chiara Racchini; Riccardo Casadei; Patrizia Simoni; Lucio Gullo
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

10.  Purinergic P2Y₁₄ receptor modulates stress-induced hematopoietic stem/progenitor cell senescence.

Authors:  Joonseok Cho; Rushdia Yusuf; Sungho Kook; Eyal Attar; Dongjun Lee; Baehang Park; Tao Cheng; David T Scadden; Byeong Chel Lee
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.